Core Viewpoint - The establishment of the China-ASEAN Regional Pharmaceutical Trading Platform has achieved significant progress, marking a mature channel for Chinese pharmaceutical companies to enter ASEAN and Shanghai Cooperation Organization countries [1][3]. Group 1: Platform Overview - The platform, initiated in January this year, is a collaborative effort between the National Medical Insurance Administration and the Guangxi Zhuang Autonomous Region government, serving as China's first cross-border regional pharmaceutical trading platform [3]. - Currently, the platform features 781 types of drugs and 1,652 categories of medical consumables and equipment, with 114 leading Chinese pharmaceutical companies and 10 foreign pharmaceutical buyers registered [3][4]. Group 2: First Cross-Border Transaction - Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. is the first Chinese pharmaceutical company to complete an online cross-border transaction through the platform, successfully supplying its product, Bailin Capsules, to a party in Singapore [3][4]. Group 3: Challenges and Solutions - Chinese pharmaceutical companies face challenges in trade information, supply chain, and transaction settlement when entering the ASEAN market. The platform provides convenient online display services and efficient transaction processes, including real-time updates on product information [4]. - The platform aims to enhance its operational mechanisms, improve transaction facilitation, promote mutual recognition of pharmaceutical regulations, and support the construction of a medical and pharmaceutical terminology database for ASEAN [4]. Group 4: Future Development - The platform is set to build a cross-border healthcare network that connects with ASEAN countries, positioning Guangxi as a hub for cross-border medical services [5].